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Abstract
Introduction: Dapsone (diaminodiphenylsulfone) is used for the treatment of intractable skin diseases such as
pemphigus and leprosy. The side effects of Dapsone are anemia, leukopenia, and liver dysfunction. Here, we
present a case of agranulocytosis-induced septic shock, which was a side effect of Dapsone.
Case presentation: An 82-year-old Japanese woman was transferred to our hospital with fever, leucopenia, and
respiratory arrest. At the previous hospital, she had been administered Dapsone for linear IgA bullous dermatosis.
At the time of admission, she presented with methemoglobinemia and septic shock, which was due to
immunosuppression caused by the normal dose of Dapsone. Although her overall health initially improved, her
condition deteriorated because of septic shock caused by an anal fistula. She died of sepsis on hospital day 80.
Conclusion: One of the side effects of Dapsone is agranulocytosis. Patients with agranulocytosis may be in danger
of developing anal fistula. Therefore, care must be taken if a patient with agranulocytosis develops a decubitus
ulcer in the sacral region, since it could develop into a fistula-in-ano.
Introduction
Dapsone (diaminodiphenylsulfone) has been used for
treating intractable skin diseases such as leprosy and
dermatitis herpetiformis. The side effects associated with
the use of Dapsone include hemolytic anemia, methe-
moglobinemia, and agranulocytosis [1]. Agranulocytosis
i sar a r ec o n d i t i o n ;h o w e v e r ,i tc a nb e c o m eal i f e - t h r e a -
tening illness if sepsis develops.
We report a case of agranulocytosis as a side effect of
Dapsone, which was administered to a patient for treat-
ing linear IgA bullous dermatosis (LABD). Agranulocy-
tosis-induced septic shock and perianal abscess
occurred, and the patient died from sepsis and multiple
organ failure.
Case presentation
An 82-year-old Japanese woman was transferred to our
emergency room with respiratory arrest and leukocyto-
penia. She had previously been admitted to a hospital
with high fever (38 to 40°C) and was treated with anti-
biotics for six days before being admitted to our hospi-
tal. She had diabetes mellitus, hyperlipidemia, and
hypertension, and she took prednisolone (15 mg/day)
and Dapsone (75 mg/day for seven days and 100 mg/
day for about six weeks) for LABD. Her physical exami-
nation, which was conducted at our hospital, revealed
the following: cold clammy skin; no jugular venous dis-
tention; no edema; no apparent skin lesions, which sug-
gested good response for LABD with Dapsone;
nonresponsiveness despite her eyes being open (Glasgow
Coma Scale score of 10, E4 V1 M5). Her blood pressure
was 100/54 mm Hg; pulse rate, irregular and tachycardia
(150 beats/minute); respiratory rate, 14 beats/minute;
SpO2, 89% (pulse oximetry, 6 L/minute O2 under intu-
bation); and body temperature, 38.3°C. No rales were
heard on auscultation.
The initial laboratory tests (Table 1) revealed a white
blood cell count of 400/μL (reference range: 4000 to
10,000 cells/μL); neutrophil count, 8 cells/μL( r e f e r e n c e
range: 2000 to 7000 cells/μL); hemoglobin, 7.6 g/dL
(reference range: 12.0 to 16.0 g/dL) and platelet count,
183 × 10
3/μL (reference range: 140 to 450 × 10
3/μL).
The results of coagulation studies were normal. Serum
chemistry showed elevated total bilirubin level, 3.0 mg/
dL (reference range: 0.2 to 1.2 mg/dL); glucose, 306 mg/
dL (reference range: 70 to 110 mg/dL) and C-reactive
protein (CRP), 21.6 mg/dL (reference range: below
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of bilirubin were indicative of hemolytic anemia,
whereas no hemolysis was shown in peripheral smear.
Further, the results of arterial blood gas (ABG) analysis,
under supplementation of 100% O2, revealed the follow-
ing: pH, 7.51; pCO2,3 0m mH g ;p O 2, 415 mm Hg; base
excess, 1.0 mmol/L; lactate, 2.2 mmol/L (reference
range: below 1.3 mmol/L) and Methemoglobin, 9.0%
(reference range: below 3.0%).
Computed tomography (CT) scans of the head
revealed no intracranial abnormalities. Chest X-ray
images revealed no infiltration. An electrocardiography
(ECG) scan revealed tachycardia (152/minute) with atrial
fibrillation. Cultures of blood, sputum, and urine sam-
ples collected at the time of admission were negative for
fungal or bacterial growth. Streptococcus pneumoniae
and Legionella were found to be absent in the urine
samples with the rapid urinary antigen detection kit.
Cerebrospinal fluid from a lumbar puncture was nega-
tive for bacteria and fungi.
Although the cause of agranulocytosis was initially
unknown, we later found that the patient was taking
Dapsone for LABD. On the basis of this finding, we
deduced that the agranulocytosis was induced by Dap-
sone, which also induced hemolytic anemia and methe-
moglobinemia, and that agranulocytosis was responsible
for her septic shock. She was subsequently admitted to
the intensive care unit (ICU) and received mechanical
ventilation. Meropenem and fosfluconazole were admi-
nistered intravenously. The levels of methemoglobine-
mia decreased to 3% because Dapsone was discontinued;
therefore, no treatment for methemoglobinemia was
required. On Day 1 after being admitted to our hospital,
her leukocyte count was lower than 400/μL; however,
after granulocyte-colony stimulating factor (G-CSF)
treatment was initiated, the leukocyte count increased to
6100/μL on Day 13. Mechanical ventilation was discon-
tinued on Day 10 because of stabilization of her circula-
tory and respiratory status. However, on Day 13 gradual
exacerbation of pneumonia caused her reintubation and
initiation of mechanical ventilation and tracheostomy
was performed on Day 15. Postsacral erosion and
induration appeared on Day 18. On the same day, her
body temperature was >39°C and atrial fibrillation
occurred (heart rate, >150/minute). Laboratory tests
revealed a white blood cell count of 26,000/μLa n dC R P
l e v e lo f1 3t o1 6m g / d L .T h i sw a si n d i c a t i v eo fp e r s i s -
tent inflammation. The postsacral region was incised,
and her decubitus ulcers were drained because exudates
with the smell of feces were discharged from the postsa-
cral region. The region was necrotized to a depth of
5 cm, and the drainage materials were found to be feces
(Figure 1). A contrast fistulogram revealed the presence
of a fistula joining the rectum to the postsacral region
(Figure 2). Inflammation was persistent, and her body
temperature increased to 39°C on Day 30 despite
repeated, almost daily, lavage, debridement, and admin-
istration of sulfadiazine silver for the fistula. Linezolid
was administered intravenously for suspected sepsis
caused by methicillin-resistant Staphylococcus aureus
(MRSA). MRSA was later identified in blood and central
venous catheter tip cultures. The blood culture was per-
sistently positive for Stenotrophomonas maltophilia after
Table 1 Laboratory investigations on admission to
Kimitsu Chuo Hospital Intensive Care Unit
Complete blood count Arterial blood gas (FIO2 1.0)
WBC 0.4 × 10
3/μL pH 7.51
RBC 2.25 × 10
6/μL pCO2 30 mmHg
Hgb 7.6 g/dL pO2 415 mmHg
Hct 22.8% HCO3 25.8 mmol/L
Plt 183 × 10
3/μL BE 1.0 mmol/L
Reticulo 27.8% Lactate 2.2 mmol/L
Met Hgb 9.0%
Coagulation studies Rapid Urinary Antigen Detection Kit
PT INR 1.19 Streptococcus pneumoniae negative
aPTT 26.9 s Legionella negative
Serum Chemistry
Alb 2.1 g/dL Na 129 mEq/L
AST 17 IU/L K 4.4 mEq/L
ALT 22 IU/L Cl 96 mEq/L
LDH 247 IU/L BUN 18.7 mg/dL
T-bil 3.0 mg/dL Cre 0.55 mg/dL
WBC: White blood cell; RBC: Red blood cell; Hgb: Hemoglobin; Hct:
Hematocrit; Plt: Platelet; Reticulo: Reticulocyte; PT INR: Prothrombin time
international normalized ratio; aPTT: Activated partial thromboplastin time;
Alb: Albumin; AST: Asparatate transaminase; ALT: Alanine transaminase; LDH:
Lactate dehydrogenase; T-bil: Total bilirubin; BUN: Blood urea nitrogen; Cre:
Creatinine; HCO3: Bicarbonate; BE: base excess; Met Hgb: Methemoglobin.
Figure 1 The appearance of fistula-in-ano at the early stage.
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Page 2 of 4Day 37, and she developed septic shock once again
along with renal failure. Her general status temporarily
improved with continuous hemodiafiltration (CHDF)
and administration of catecholamines. Although colost-
omy was performed on Day 55, she died on Day 80
because of persistent shock and gastrointestinal hemor-
rhage (Figure 3).
Discussion
Dapsone has been used for treating leprosy since the
1940s, and a few dermatological disorders of autoim-
mune origin since the 1950s [1,2]. It is also effective for
dermatological conditions such as dermatitis herpetifor-
mis, LABD, bullous pemphigoid, pemphigus, and
erythema elevatum diutinum. Dapsone also has antibac-
terial and anti-inflammatory effects. The mechanism
underlying the former is the inhibition of bacterial
synthesis of folate; however, the mechanism underlying
the anti-inflammatory effect is unknown [2]. The recom-
mended dose of Dapsone is 50 to 100 mg. Usually, ser-
ious side effects are not observed when the dose is <100
mg/day; however, they do occur when the dose is >200
mg/day. Moreover, it is recommended that the dose
should not exceed 300 mg/day [2].
The most common side effects of Dapsone are hemoly-
tic anema, methemoglobinemia, and agranulocytosis [1].
Hemolytic anemia is a dose-dependent side effect that
usually occurs three to four weeks after Dapsone therapy
is initiated if the dose is >300 mg/day [2]. Although the
mechanism underlying the side effects is unknown, it has
been reported that Dapsone reduces the lifespan of red
blood cells [2]. The level of methemoglobinemia increases
in a dose-dependent manner, especially in infants and
elderly patients. The common symptoms of methemoglo-
binemia are headache, dyspnea, and tachycardia. Careful
observation is required when the percentage of methemo-
globin is approximately 10 to 20% and if a patient does
not exhibit the above mentioned symptoms. Dapsone
therapy should be discontinued for patients with abnormal
cardiopulmonary function when the percentage of methe-
mogloblin is 5%. The fundamental treatment for methe-
mogloblinemia is careful observation. Severe cases of
methemoglobinemia, however, can be treated with intrave-
nous methylene blue (1 to 2 mg/kg). In a well-known
study, it was reported that agranulocytosis developed in 16
US soldiers in Vietnam who were receiving Dapsone pro-
phylaxis for falciparum malaria [3]. Agranulocytosis devel-
ops 4 to 12 weeks after Dapsone therapy is initiated, and it
gradually progresses. The initial symptoms are fever, swel-
ling of the lymph nodes, and inflammation and ulcers of
the oral cavity, pharynx, and esophagus. Once agranulocy-
tosis develops, a patient’s increased susceptibility to sepsis
and death may occur. However, unlike methemoglobine-
mia, agranulocytosis is not a dose-dependent side effect of
Dapsone, and the mechanism of agranulocytosis due to
Dapsone remains unknown.
In our case, the cause of shock along with agranulocy-
tosis was initially unknown. Methemoglobinemia was
recognized because the patient’sP a O 2 level was high
despite the low SpO2 level. We found that she had taken
Dapsone, a side effect of which was methemoglobinemia,
Figure 2 Fistulogram showing a fistula communicating
between the rectum and the postsacral region.
Figure 3 Clinical course of a patient with Dapsone-induced
agranulocytosis. BT: Body temperature; CHDF: Continuous
hemodiafiltration; CRP: C-reactive protein; G-CSF: Granulocyte
colony-stimulating factor; MRSA: Methicillin-resistant Staphylococcus
aureus; WBC: White blood cell
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induced agranulocytosis [4]. Although the patient took
only 100 mg per day for 45 days, she developed severe
agranulocytosis as a side effect. In the 1970s and 1980s,
there were many studies that reported the side effects of
Dapsone, and almost all these studies reported that Dap-
sone-induced side effects occurred when a few hundred
milligrams to a few grams of Dapsone were administered
to patients. However, it was also reported that 50 to 125
mg of Dapsone induced severe agranulocytosis. Patients
taking Dapsone for dermatitis herpetiformis are at a 25-
to 33-fold greater risk of agranulocytosis than normal [1].
Careful observation is required when treating with Dap-
sone for an inflammatory disease such as LABD. Her
hemoglobin prior to initiation of Dapsone therapy was
13.7 g/dL. No blood tests were performed during Dap-
sone therapy because of the normal hemoglobin level. In
order to monitor anemia, leukocytopenia, and methemo-
globinemia, blood tests are required every week for the
first month, and only every two weeks to every month
thereafter, even if patients are administered 100 mg/day
of Dapsone.
The patient recovered once from septic shock, but she
eventually died of multiple organ failure due to recur-
rent sepsis from an anal fistula that developed from a
decubitus ulcer of the sacral region. In most cases, the
causes of fistula-in-ano are radiation therapy and surgi-
cal complication. Anal fistula is a frequent complication
of leukemia and agranulocytosis. It has been reported
that 8 to 60% of leukemia patients develop perianal and
perirectal infection; however, the exact figure is
unknown [5,6]. To our knowledge, Dapsone-induced
agranulocytosis that develops to fistula-in-ano has not
been previously reported. Although the reason patients
with leukemia and agranulocytosis tend to develop fis-
tula-in-ano is unknown, it is speculated that decubitus,
which is caused by prolonged immobility, develops into
an abscess because of dysfunction; when this is accom-
panied by a decrease in the number of granulocytes,
which are responsible for immune response, the decubi-
tus develops into an anal fistula [7]. The treatment
approach for fistula-in-ano is appropriate antibiotic
administration and incisional drainage, provided that
background diseases such as agranulocytosis and leuke-
mia can be controlled and the patient’s overall condition
permits it [8,9]. Sepsis-associated fistula-in-ano increases
the mortality rate even if incisional drainage is properly
performed. In our case, we performed incisional drai-
nage soon after the diagnosis of fistula-in-ano was
made; it was followed by antibiotic administration and
several debridements. The patient died of sepsis without
resolution of the anal fistula; however, we could have
performed the incisional drainage earlier if we could
have predicted the development of the decubitus ulcer
in the sacral region into the anal fistula and if we had
conducted a rectal examination. The development of fis-
tula-in-ano should always be considered for patients
with Dapsone-induced agranulocytosis, and it is neces-
sary to examine for infection around the rectum when a
decubitus ulcer is formed in the sacral region.
Conclusion
We report the case of a patient with Dapsone-induced
agranulocytosis that progressed to septic shock. She
temporarily recovered from septic shock but eventually
died when the infection could not be controlled. Inci-
sional drainage was performed for anal fistula, which
developed from a decubitus ulcer in the sacral region.
A g r a n u l o c y t o s i si so n eo ft h es i d ee f f e c t so fD a p s o n e ;
therefore, it should be administered with care. Further,
for patients with agranulocytosis, if a decubitus ulcer is
found in the sacral region, it should be monitored care-
fully because it may develop into fistula-in-ano.
Consent
Written informed consent was obtained from the
patient’s daughter for publication of this case report and
accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
Authors’ contributions
YK wrote the case report, conducted the literature search and obtained the
consent. DS contributed to the discussion. NK supervised and edited the
case report. All authors were involved with treatment of this patient and all
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 11 June 2010 Accepted: 16 March 2011
Published: 16 March 2011
References
1. Coleman MD: Dapsone-mediated agranulocytosis: risks, possible
mechanisms and prevention. Toxicology 2001, 162:53-60.
2. Zuidema J, Hilbers-Modderman ES, Merkus FW: Clinical pharmacokinetics
of Dapsone. Clin Pharmacokinet 1986, 11:299-315.
3. Ognibene AJ: Agranulocytosis due to Dapsone. Ann Intern Med 1970,
72:521-524.
4. Trillo RA Jr, Aukburg S: Dapsone-induced methemoglobinemia and pulse
oximetry. Anesthesiology 1992, 77:594-596.
5. Schimpff SC, Wiernik PH, Block JB: Rectal abscesses in cancer patients.
Lancet 1972, 300:844-847.
6. Sehdev MK, Dowling MD Jr, Seal SH, Stearns MW Jr: Perianal and anorectal
complications in leukemia. Cancer 1973, 31:149-152.
7. Vanhueverzwyn R, Delannoy A, Michaux JL, Dive C: Anal lesions in
hematologic diseases. Dis Colon Rectum 1980, 23:310-312.
8. Rickard MJ: Anal abscesses and fistulas. ANZ J Surg 2005, 75:64-72.
9. Marcus RH, Stine RJ, Cohen MA: Perirectal abscess. Ann Emerg Med 1995,
25:597-603.
doi:10.1186/1752-1947-5-107
Cite this article as: Kobe et al.: Dapsone-induced agranulocytosis
leading to perianal abscess and death: a case report. Journal of Medical
Case Reports 2011 5:107.
Kobe et al. Journal of Medical Case Reports 2011, 5:107
http://www.jmedicalcasereports.com/content/5/1/107
Page 4 of 4